About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.



  • 2009 Co-promotion agreement with Lundbeck for Ebixa®, a treatment for Alzheimer’s disease
  • Amosartan®, an antihypertensive combination drug of Amodipine and Losartan, launched
  • Co-promotion agreement with GSK in respiration-allergy area
  • 2008 Hanmi-Crystal genomics strategic alliance
  • 2007 KGMP approval on Cephalosporin finished product manufacturing facility in Pyongtaek .
  • First launching of anti-obesity drug ‘Slimmer®’(sibutramine mesilate)
  • 2006 < Successful development of Mexibufen Syrup, using alternative salt
  • Published clinical study for Amodipine®
  • 2004 Patent of Amodipine, a new salt form of Amlodipine, granted
  • Successful development of Fedipine table, a 24hr controlled-release formulation of Nifedipine
  • 2003 Registered as Hanmi Photographic Museum with government
  • Hanmi Pharm. marking its 30-year foundation day anniversary
  • Changes into Hanmi Pharmaceutical Co., Lt
  • Designation of Hanmi’s central research labs as ‘ICE GMP Technology Center’
  • 2002 Establishment of Hanmi Foundation of Art & Culture
  • Completion of Hanmi GMP plant in Beijing
  • 2001 Development of oral antifungal agent ‘Itra tablet’ for 2nd in the world
  • 2000 Successful development of oral anticancer drug Paclitaxel